Loading…
Employees: 139
Size JS Link (127120.KS) is a South Korea Health Care company (Medical/Nursing Services) with a market value of $481M, the 341st largest of 495 South Korea companies the cockpit tracks. Shares closed at ₩17,440 on 6 Nov 2026.
Performance Over six months the shares fell 57.2%, against -1.1% for the median peer and -24.5% for the South Korea market (cap-weighted) — lowest of 19 in its peer set.
Growth Revenue grew 51.3% over the last twelve months (peer median +6.0%); the operating margin is -76.2% (peer median 8.4%).
Valuation It trades at 28.2× enterprise value to sales against a peer median of 1.4× (most expensive of 21).
Capital Return on invested capital runs 21.1 points below its cost of capital (7.2% WACC).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | ₩22.8B | ₩19.3B | ₩15.9B | ₩21.9B | ₩17.0B |
| Revenue growth | — | +21% | -28% | +29% | — |
| Gross profit | ₩2.81B | ₩2.28B | ₩1.84B | ₩4.60B | ₩2.36B |
| EBITDA | -₩12.8B | -₩12.5B | -₩7.47B | -₩2.71B | -₩3.46B |
| Net income | -₩5.30B | -₩16.4B | -₩10.8B | -₩5.60B | -₩7.78B |
| Free cash flow | -₩45.2B | -₩53.4B | -₩23.5B | -₩7.91B | -₩4.02B |
| Capital expenditure | ₩27.6B | ₩44.1B | ₩16.7B | ₩2.89B | ₩5.09B |
| Total debt | ₩63.6B | ₩43.3B | ₩19.1B | ₩4.32B | ₩6.09B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 127120.KS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -37.4% | -5.7% | 2nd lowest of 21 |
| 6-month return | -57.2% | -1.1% | lowest of 19 |
| Distance from 52-week high | -65.0% | -23.3% | lowest of 21 |
| Revenue growth (TTM) | +51.3% | +6.0% | 2nd highest of 21 |
| Operating margin | -76.2% | 8.4% | 2nd lowest of 21 |
| EV / Sales | 28.2× | 1.4× | most expensive of 21 |
| ROIC minus cost of capital | -21.1 pp | -1.0 pp | 5th lowest of 20 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| JS Link 127120.KS | South Korea | $481M | -57% | +51% | -76% | 28.2× | n/a | n/a |
| Strata Critical Medical SRTA | United States | $497M | 0% | +23% | -4% | 1.6× | n/a | n/a |
| Integral Diagnostics IDX.AX | Australia | $450M | -21% | +26% | 9% | 1.5× | 8.3% | +17.7% |
| Jeena Sikho Lifecare JSLL.NS | India | $424M | -56% | +162% | 36% | 4.7× | 8.1% | +42.6% |
| Australian Clinical Labs ACL.AX | Australia | $419M | +74% | -1% | 8% | 1.3× | 3.9% | +2.6% |
| ADICON 9860.HK | Hong Kong | $408M | +9% | +1% | 4% | 1.3× | 12.0% | -1.5% |
| Shanghai Labway Clinical Laboratory 301060.SZ | China | $593M | -4% | -19% | 6% | 2.7× | 8.8% | +3.2% |
| Tellgen 300642.SZ | China | $387M | -3% | +5% | 8% | 6.2× | 22.4% | -5.8% |
| M1 Kliniken M12.DE | Germany | $376M | +3% | -28% | 13% | 1.2× | -5.5% | +17.9% |
| Oncology Institute STLN | United States | $362M | n/a | +38% | -4% | 0.7× | n/a | n/a |
| Nephrocare Health Services NEPHROPLUS.NS | India | $639M | +10% | +33% | 14% | 5.8× | 35.7% | +31.6% |
| Fulgent Genetics FLGT | United States | $653M | +49% | +7% | -36% | 1.2× | n/a | n/a |
| Australian Unity Ltd Pref AYUPA.AX | Australia | $353M | +6% | 0% | -2% | 0.4× | -15.1% | +9.6% |
| NIOX NIOX.L | United Kingdom | $349M | +2% | +3% | 22% | 5.1× | 3.9% | +15.3% |
| Auna AUNA | United States | $346M | -8% | +17% | 13% | 1.0× | -10.5% | +24.4% |
| GMR Solutions GMRS | United States | $672M | n/a | -4% | 14% | 0.9× | -20.0% | -4.0% |
| Universal Vision Biotechnology 3218.TWO | Taiwan | $324M | -7% | 0% | 31% | 2.6× | -12.3% | +15.4% |
| HK inno.N 195940.KS | South Korea | $745M | -32% | +7% | 12% | 0.9× | -10.8% | +12.2% |
| WELL Health Technologies WELL.TO | Canada | $760M | -5% | +39% | 7% | 1.4× | 9.1% | +94.5% |
| Ginkgo Bioworks DNA | United States | $760M | +26% | -52% | -258% | 7.7× | n/a | n/a |
| Jinxin Fertility 1951.HK | Hong Kong | $800M | -2% | +7% | 11% | 2.9× | 18.0% | +12.4% |